


## CLAIMS

1. A compound of formula (I):



(I)

5 A represents an optionally substituted aryl, or an optionally substituted 5- or 6- membered heterocycl ring, or an optionally substituted bicyclic heterocycl group;  
 B represents a phenyl or pyridyl ring;  
 Z represents O, S, SO, or  $SO_2$ ;

10  $R^1$  represents  $CO_2R^4$ , CN,  $CONR^5R^6$ ,  $CH_2CO_2R^4$ , OR<sup>4</sup>, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted  $SO_2$ alkyl,  $SO_2NR^5R^6$ ,  $NR^5CONR^5R^6$ , COalkyl, 2H-tetrazol-5-yl-methyl, optionally substituted bicyclic heterocycle or optionally substituted heterocycl;

15  $R^{2a}$  and  $R^{2b}$  each independently represents hydrogen, halogen, optionally substituted alkyl, optionally substituted alkoxy, CN,  $SO_2$ alkyl,  $SR^5$ ,  $NO_2$ , optionally substituted aryl,  $CONR^5R^6$  or optionally substituted heteroaryl;

20  $R^x$  represents optionally substituted alkyl wherein 1 or 2 of the non-terminal carbon atoms are optionally replaced by a group independently selected from NR<sup>4</sup>, O and  $SO_n$ , wherein n is 0, 1 or 2: or  $R^x$  represents optionally substituted  $CQ^aQ^b$ -heterocycl, optionally substituted  $CQ^aQ^b$ -bicyclic heterocycl or optionally substituted  $CQ^aQ^b$ -aryl;

25  $R^4$  represents hydrogen or an optionally substituted alkyl;  
 $R^5$  represents hydrogen or an optionally substituted alkyl;  
 $R^6$  represents hydrogen or optionally substituted alkyl, optionally substituted heteroaryl, optionally substituted  $SO_2$ aryl, optionally substituted  $SO_2$ alkyl, optionally substituted  $SO_2$ heteroaryl, CN, optionally substituted  $CQ^aQ^b$ aryl, optionally substituted  $CQ^aQ^b$ heteroaryl or COR<sup>7</sup>;

30  $R^7$  represents hydrogen, optionally substituted alkyl, optionally substituted heteroaryl or optionally substituted aryl;  
 $R^8$  represents hydrogen, Cl,  $CF_3$ , or  $C_{1-3}$ alkyl;  
 $R^9$  represents halogen, hydrogen,  $CF_3$ , or  $C_{1-3}$ alkyl;  
 $Q^a$  and  $Q^b$  are each independently selected from hydrogen and  $CH_3$ ;

wherein when A is a 6-membered ring the  $R^1$  substituent and pyrrole ring are attached to carbon atoms 1,2-, 1,3- or 1,4- relative to each other, and when A is a five-membered ring

or bicyclic heterocycl group the R<sup>1</sup> substituent and phenyl ring are attached to substitutable carbon atoms 1,2- or 1,3- relative to each other; and derivatives thereof.

- 5 2. A compound according to claim 1 wherein A is optionally substituted phenyl, optionally substituted pyridyl or optionally substituted isoquinolinyl.
- 10 3. A compound according to claim 1 selected from the compounds of Examples 1 to 80 and derivatives thereof.
- 15 4. A pharmaceutical composition comprising a compound according to any one of claims 1 to 3 or a pharmaceutically acceptable derivative thereof together with a pharmaceutical carrier and/or excipient.
- 20 5. A compound according to any one of claims 1 to 3 or a pharmaceutically acceptable derivative thereof for use as an active therapeutic substance.
6. A compound according to any one of claims 1 to 3 or a pharmaceutically acceptable derivative thereof for use in the treatment of a condition which is mediated by 20 the action of PGE<sub>2</sub> at EP<sub>1</sub> receptors.
- 25 7. A method of treating a human or animal subject suffering from a condition which is mediated by the action of PGE<sub>2</sub> at EP<sub>1</sub> receptors which comprises administering to said subject an effective amount of a compound according to any one of claims 1 to 3 or a pharmaceutically acceptable derivative thereof.
- 30 8. A method of treating a human or animal subject suffering from inflammatory pain, neuropathic pain or visceral pain which method comprises administering to said subject an effective amount of a compound according to any one of claims 1 to 3 or a pharmaceutically acceptable derivative thereof.
- 35 9. Use of a compound according to any one of claims 1 to 3 or a pharmaceutically acceptable derivative thereof for the manufacture of a medicament for the treatment of a condition which is mediated by the action of PGE<sub>2</sub> at EP<sub>1</sub> receptors.
10. Use of a compound according to any one of claims 1 to 3 or a pharmaceutically acceptable derivative thereof for the manufacture of a medicament for the treatment or prevention of a condition such as inflammatory pain, neuropathic pain or visceral pain.